

Hugo Vanderstichele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10949982/publications.pdf>

Version: 2024-02-01

89
papers

13,533
citations

43973

48
h-index

49773

87
g-index

91
all docs

91
docs citations

91
times ranked

10375
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. <i>Annals of Neurology</i> , 2009, 65, 403-413.	2.8	1,803
2	Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. <i>Nature</i> , 1998, 391, 387-390.	13.7	1,765
3	Cerebrospinal Fluid β -Amyloid(1-42) in Alzheimer Disease. <i>Archives of Neurology</i> , 1999, 56, 673.	4.9	594
4	Evaluation of CSF-tau and CSF-A β 242 as Diagnostic Markers for Alzheimer Disease in Clinical Practice. <i>Archives of Neurology</i> , 2001, 58, 373-9.	4.9	487
5	Tau and A β 242 in Cerebrospinal Fluid from Healthy Adults 21-93 Years of Age: Establishment of Reference Values. <i>Clinical Chemistry</i> , 2001, 47, 1776-1781.	1.5	420
6	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. <i>Archives of Neurology</i> , 2010, 67, 949.	4.9	407
7	Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. <i>Neuroscience Letters</i> , 2001, 297, 187-190.	1.0	401
8	Simultaneous Measurement of β -Amyloid(1-42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology. <i>Clinical Chemistry</i> , 2005, 51, 336-345.	1.5	400
9	Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2004, 61, 95.	13.8	390
10	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.4	354
11	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.4	344
12	CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 154-165.	1.7	329
13	Standardization of measurement of β -amyloid(1-42) in cerebrospinal fluid and plasma. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000, 7, 245-258.	1.4	286
14	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2012, 8, 65-73.	0.4	271
15	Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. <i>Acta Neuropathologica</i> , 2011, 121, 597-609.	3.9	256
16	Evaluation of plasma A β 40 and A β 242 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 357-367.	1.5	242
17	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017, 13, 45-58.	0.4	227
18	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. <i>Neurobiology of Aging</i> , 2008, 29, 1143-1159.	1.5	217

#	ARTICLE	IF	CITATIONS
19	Prominent Cerebral Amyloid Angiopathy in Transgenic Mice Overexpressing the London Mutant of Human APP in Neurons. <i>American Journal of Pathology</i> , 2000, 157, 1283-1298.	1.9	213
20	Cerebrospinal Fluid Markers for Alzheimer's Disease Evaluated after Acute Ischemic Stroke. <i>Journal of Alzheimer's Disease</i> , 2000, 2, 199-206.	1.2	183
21	Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of $\text{A}\beta_{1-42}$, Total tau, and P-tau ₁₈₁ for Identifying Alzheimer Disease Amyloid Plaque Pathology. <i>Archives of Neurology</i> , 2011, 68, 1137.	4.9	161
22	The discrepancy between presenilin subcellular localization and $\text{A}\beta$ -secretase processing of amyloid precursor protein. <i>Journal of Cell Biology</i> , 2001, 154, 731-740.	2.3	155
23	Effects of Processing and Storage Conditions on Amyloid $\text{A}\beta_{1-42}$ and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice. <i>Clinical Chemistry</i> , 2005, 51, 189-195.	1.5	151
24	Factors affecting $\text{A}\beta_{1-42}$ plasma levels and their utility as biomarkers in ADNI. <i>Acta Neuropathologica</i> , 2011, 122, 401-13.	3.9	151
25	Analytical performance and clinical utility of the INNOTEST [®] PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 1472-80.	1.4	145
26	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	4.9	144
27	Cerebrospinal fluid levels of total-tau, phospho-tau and Abeta42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 47-51.	1.0	140
28	Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years. <i>Journal of Alzheimer's Disease</i> , 2007, 12, 255-260.	1.2	117
29	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 53-61.	0.4	114
30	Plasma Levels of $\text{A}\beta_{1-40}$, $\text{A}\beta_{1-42}$, and Total $\text{A}\beta$ Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins. <i>Archives of Neurology</i> , 2004, 61, 333.	4.9	109
31	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	3.7	109
32	Aging Increased Amyloid Peptide and Caused Amyloid Plaques in Brain of Old APP/V717I Transgenic Mice by a Different Mechanism than Mutant Presenilin1. <i>Journal of Neuroscience</i> , 2000, 20, 6452-6458.	1.7	107
33	CSF $\text{A}\beta_{1-42}$ an excellent but complicated Alzheimer's biomarker a route to standardisation. <i>Clinica Chimica Acta</i> , 2017, 467, 27-33.	0.5	104
34	The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer's Disease, Reflecting a Common Pathophysiological Process. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 257-264.	0.7	102
35	Differential role of CSF fatty acid binding protein 3, α -synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 52.	3.0	101
36	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. <i>Neurobiology of Aging</i> , 2008, 29, 812-818.	1.5	94

#	ARTICLE	IF	CITATIONS
37	Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 13-20.	1.2	94
38	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333.	0.4	87
39	Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. <i>Methods</i> , 2012, 56, 484-493.	1.9	85
40	Amino-Truncated β -Amyloid ₄₂ Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment. <i>Clinical Chemistry</i> , 2005, 51, 1650-1660.	1.5	82
41	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 772-791.	0.4	79
42	Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 871-882.	1.8	79
43	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β ₄₂ . <i>Biomarkers in Medicine</i> , 2012, 6, 409-417.	0.6	76
44	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. <i>Neurobiology of Aging</i> , 2010, 31, 1867-1876.	1.5	63
45	Relevance of $A\beta_{42/40}$ Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 138.	1.7	59
46	Improved protocol for measurement of plasma β -amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. , 2012, 8, 250-260.		56
47	A user's guide for τ biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017, 32, 1117-1130.	2.2	54
48	How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the $A\beta_{42}/A\beta_{40}$ ratio. , 2017, 13, 885-892.		52
49	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. <i>Alzheimer's and Dementia</i> , 2021, 17, 1575-1582.	0.4	51
50	Cerebrospinal fluid τ , and β -amyloid(1-42) in dementia disorders. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 2005-2011.	2.2	50
51	Cerebrospinal Fluid Collection Tubes: A Critical Issue for Alzheimer Disease Diagnosis. <i>Clinical Chemistry</i> , 2012, 58, 787-789.	1.5	50
52	Assessing the commutability of reference material formats for the harmonization of amyloid- β measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1177-1191.	1.4	49
53	Evidence That $A\beta_{42}$ Plasma Levels in Presenilin-1 Mutation Carriers Do not Allow for Prediction of Their Clinical Phenotype. <i>Neurobiology of Disease</i> , 1999, 6, 280-287.	2.1	48
54	The Glu318Gly Substitution in Presenilin 1 Is Not Causally Related to Alzheimer Disease. <i>American Journal of Human Genetics</i> , 1999, 64, 290-292.	2.6	47

#	ARTICLE	IF	CITATIONS
55	C-Reactive Protein, Plasma Amyloid- β Levels, and Their Interaction With Magnetic Resonance Imaging Markers. <i>Stroke</i> , 2018, 49, 2692-2698.	1.0	46
56	Antibody-based methods for the measurement of β -synuclein concentration in human cerebrospinal fluid – method comparison and round robin study. <i>Journal of Neurochemistry</i> , 2019, 149, 126-138.	2.1	44
57	Plasma Amyloid- β Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 977-987.	1.2	43
58	First amyloid β 1-42 certified reference material for re-calibrating commercial immunoassays. <i>Alzheimer's and Dementia</i> , 2020, 16, 1493-1503.	0.4	42
59	Comparison of Two Analytical Platforms for the Clinical Qualification of Alzheimer's Disease Biomarkers in Pathologically-Confirmed Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 117-131.	1.2	40
60	Plasma amyloid- β levels, cerebral atrophy and risk of dementia: a population-based study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 63.	3.0	39
61	Ultrasensitive Detection of Plasma Amyloid- β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 775-783.	1.2	38
62	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 19-35.	1.2	35
63	Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. <i>Alzheimer's and Dementia</i> , 2017, 13, 701-709.	0.4	35
64	Validation of a Multiplex Assay for Simultaneous Quantification of Amyloid- β Peptide Species in Human Plasma with Utility for Measurements in Studies of Alzheimer's Disease Therapeutics. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 905-918.	1.2	29
65	Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 55-67.	1.2	27
66	Plasma A β (Amyloid- β) Levels and Severity and Progression of Small Vessel Disease. <i>Stroke</i> , 2018, 49, 884-890.	1.0	27
67	Commutability of the certified reference materials for the standardization of β -amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β -amyloid 1-40 measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 2058-2066.	1.4	27
68	Analytical aspects of molecular Alzheimer's disease biomarkers. <i>Biomarkers in Medicine</i> , 2012, 6, 377-389.	0.6	26
69	Cerebrospinal Fluid Total and Phosphorylated β -Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy. <i>Molecular Neurobiology</i> , 2019, 56, 3476-3483.	1.9	26
70	Validation of ELISA Methods for Quantification of Total Tau and Phosphorylated-Tau181 in Human Cerebrospinal Fluid with Measurement in Specimens from Two Alzheimer's Disease Studies. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 531-541.	1.2	23
71	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 169-183.	1.2	21
72	Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients. <i>European Journal of Paediatric Neurology</i> , 2008, 12, 334-341.	0.7	20

#	ARTICLE	IF	CITATIONS
73	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 97-106.	1.2	20
74	Validation of Assays for Measurement of Amyloid- β Peptides in Cerebrospinal Fluid and Plasma Specimens from Patients with Alzheimer's Disease Treated with Solanezumab. Journal of Alzheimer's Disease, 2013, 34, 897-910.	1.2	17
75	Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, β -synuclein, and total tau in combination with $A\beta(1-42)/A\beta(1-40)$. Alzheimer's Research and Therapy, 2017, 9, 40.	3.0	17
76	Unaltered Plasma Levels of β -Amyloid ₍₁₋₄₀₎ and β -Amyloid ₍₁₋₄₂₎ upon Stimulation of Human Platelets. Dementia and Geriatric Cognitive Disorders, 2003, 16, 93-97.	0.7	16
77	Neurotoxicity Marker Profiles in the CSF are not Age-Dependent but Show Variation in Children Treated for Acute Lymphoblastic Leukemia. NeuroToxicology, 2004, 25, 471-480.	1.4	16
78	No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. Molecular Neurodegeneration, 2016, 11, 65.	4.4	16
79	Potential sources of interference on Abeta immunoassays in biological samples. Alzheimer's Research and Therapy, 2012, 4, 39.	3.0	14
80	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. Alzheimer's Research and Therapy, 2016, 8, 42.	3.0	14
81	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	1.7	13
82	Accelerating drug development for Alzheimer's disease through the use of data standards. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 273-283.	1.8	10
83	Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults. Journal of Neurochemistry, 2019, 149, 139-157.	2.1	10
84	Differences and Similarities between Two Frequently Used Assays for Amyloid β 42 in Cerebrospinal Fluid. Clinical Chemistry, 2005, 51, 1057-1060.	1.5	9
85	A First Tetraplex Assay for the Simultaneous Quantification of Total β -Synuclein, Tau, β -Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. PLoS ONE, 2016, 11, e0153564.	1.1	6
86	Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays. SLAS Technology, 2018, 23, 188-197.	1.0	5
87	Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach. Alzheimer's Research and Therapy, 2014, 6, 23.	3.0	3
88	O4-11-06: The confidence level of established cut-off values for CSF Alzheimer's disease-specific biomarkers. , 2015, 11, P298-P298.		2
89	Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for β -synuclein measurement. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1653-1661.	1.4	2